NASDAQ:ADXS Ayala Pharmaceuticals (ADXS) Stock Price, News & Analysis → Exposed: 3 CENT Crypto to Explode June 24th? (From True Market Insiders) (Ad) Free ADXS Stock Alerts $0.26 -0.02 (-7.12%) (As of 06/14/2024 ET) Add Compare Share Share Today's Range$0.26▼$0.2850-Day Range$0.14▼$0.6752-Week Range$0.14▼$1.95Volume5,870 shsAverage Volume8,250 shsMarket Capitalization$2.81 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsTrends Get Ayala Pharmaceuticals alerts: Email Address Ad Paradigm PressDiscover How to Turn $10,000 into $1 MillionToday, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.That will slam shut June 25. About Ayala Pharmaceuticals Stock (NASDAQ:ADXS)Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.Read More ADXS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ADXS Stock News HeadlinesJune 12 at 2:55 AM | americanbankingnews.comAyala Pharmaceuticals (NASDAQ:ADXS) Receives New Coverage from Analysts at StockNews.comMay 9, 2024 | globenewswire.comAyala Pharmaceuticals Files Form 15 to Voluntarily Deregister and Suspend its Reporting ObligationsApril 2, 2024 | seekingalpha.comImmunome: An Oncology Powerhouse In The MakingMarch 26, 2024 | globenewswire.comAyala Pharmaceuticals Announces Completion of Sale of AL102 to ImmunomeMarch 16, 2024 | finance.yahoo.comIMNM Oct 2024 22.500 callMarch 16, 2024 | finance.yahoo.comIMNM Oct 2024 25.000 callMarch 16, 2024 | finance.yahoo.comIMNM Oct 2024 25.000 putMarch 16, 2024 | finance.yahoo.comIMNM Oct 2024 45.000 callFebruary 20, 2024 | businesswire.comImmunome Recognizes Ayala Pharmaceuticals' Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid TumorsFebruary 10, 2024 | msn.comAdvaxis Executes Strategic Unregistered Equity SalesFebruary 7, 2024 | msn.comAdvaxis Announces Definitive Agreement with Ayala PharmaceuticalsFebruary 6, 2024 | msn.comImmunome to buy AL102, a phase 3 asset for treatment of desmoid tumorsFebruary 6, 2024 | finance.yahoo.comImmunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala PharmaceuticalsNovember 24, 2023 | morningstar.comAyala Pharmaceuticals Inc Ordinary Shares ADXSNovember 20, 2023 | sfgate.comAyala Pharmaceuticals: Fiscal Q4 Earnings SnapshotNovember 17, 2023 | msn.comLadenburg Thalmann Downgrades Ayala Pharmaceuticals (ADXS)October 23, 2023 | finance.yahoo.comAyala Pharmaceuticals Presents Updated AL102 Results from Phase 2 Clinical Trial in Desmoid Tumors at ESMO Congress 2023October 19, 2023 | finance.yahoo.comAyala Pharmaceuticals Announces Closing of Merger with BiosightAugust 10, 2023 | finance.yahoo.comAyala Pharmaceuticals Announces Second Quarter 2023 Financial Results and Provides Corporate UpdateAugust 3, 2023 | investing.comAyala Pharmaceuticals Inc (ADXS)August 1, 2023 | finance.yahoo.comAyala Pharmaceuticals Announces Abstracts on AL102 and AL101 Accepted for Presentation at ESMO Congress 2023July 27, 2023 | finance.yahoo.comAyala Pharmaceuticals and Biosight Enter into Definitive Merger AgreementJuly 5, 2023 | finance.yahoo.comAyala Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA Regarding AL102 for the Treatment of Desmoid TumorsJune 5, 2023 | finance.yahoo.comUpdated RINGSIDE Phase 2 Results Featured in Poster Discussion Session at 2023 American Society of Clinical Oncology (ASCO) Annual MeetingMay 25, 2023 | finance.yahoo.comAyala Pharmaceuticals Announces Updated RINGSIDE Phase 2 Results at 2023 American Society of Clinical Oncology (ASCO) Annual MeetingSee More Headlines Receive ADXS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ayala Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/16/2024Today6/15/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ADXS CUSIPN/A CIK1100397 Webwww.ayalapharma.com Phone609-452-9813Fax609-452-9818EmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)($7.98) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-48,070,000.00 Net MarginsN/A Pretax Margin-399,876.94% Return on Equity-3,967.23% Return on Assets-339.10% Debt Debt-to-Equity RatioN/A Current Ratio0.30 Quick Ratio0.30 Sales & Book Value Annual Sales$10,000.00 Price / Sales280.58 Cash FlowN/A Price / Cash FlowN/A Book Value($2.27) per share Price / Book-0.11Miscellaneous Outstanding Shares10,750,000Free Float10,684,000Market Cap$2.81 million OptionableNot Optionable Beta1.45 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. Ruth Ben Yakar Ph.D. (Age 54)Chief Exec. Officer Dr. Stela Gangrenovitch Ph.D.Co-Founder, Chief Scientist Officer and DirectorMr. Mark Gengrinovitch LLBCo-Founder, Chief Financial Officer and DirectorKey CompetitorsElevai LabsNASDAQ:ELABLongeveronNASDAQ:LGVNImunonNASDAQ:IMNNCan-Fite BioPharmaNYSE:CANFMIRA PharmaceuticalsNASDAQ:MIRAView All Competitors ADXS Stock Analysis - Frequently Asked Questions Should I buy or sell Ayala Pharmaceuticals stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ayala Pharmaceuticals in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ADXS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ADXS, but not buy additional shares or sell existing shares. View ADXS analyst ratings or view top-rated stocks. How have ADXS shares performed in 2024? Ayala Pharmaceuticals' stock was trading at $0.6670 at the beginning of 2024. Since then, ADXS shares have decreased by 60.9% and is now trading at $0.2610. View the best growth stocks for 2024 here. How were Ayala Pharmaceuticals' earnings last quarter? Ayala Pharmaceuticals, Inc. (NASDAQ:ADXS) announced its quarterly earnings data on Tuesday, April, 16th. The company reported ($2.96) earnings per share (EPS) for the quarter. What other stocks do shareholders of Ayala Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ayala Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Madrigal Pharmaceuticals (MDGL), Merck & Co., Inc. (MRK), Anavex Life Sciences (AVXL), Vistagen Therapeutics (VTGN), Novavax (NVAX), Highpower International (HPJ), OPKO Health (OPK) and Athersys (ATHX). How do I buy shares of Ayala Pharmaceuticals? Shares of ADXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ADXS) was last updated on 6/15/2024 by MarketBeat.com Staff From Our PartnersExposed: 3 CENT Crypto to Explode June 24th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredJeff Bezos & 48 Members of Congress Are Buying ONE Sector…Why are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Con...InvestorPlace | SponsoredTiny, One-Half Inch Pellet the Key to INFINITE Energy?It’s a tiny, $1 billion company that holds the key to this power. And yet, it’s the largest company of its ...Eagle Publishing | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredHurry! Buy this stock before the Robinhood traders do!Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ayala Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ayala Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.